Land: Malta
Språk: engelska
Källa: Medicines Authority
CYTARABINE
Fresenius Kabi Oncology PLC Lion Court, Farnham Road, Bordon, Hampshire, GU35 0NF, United Kingdom
L01BC01
CYTARABINE 100 mg/ml
SOLUTION FOR INFUSION OR INJECTION
CYTARABINE 100 mg/ml
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2013-01-10
Page 1 of 10 PACKAGE LEAFLET: INFORMATION FOR THE USER CYTARABINE 100 MG/ML SOLUTION FOR INJECTION OR INFUSION CYTARABINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor or pharmacist. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Cytarabine is and what it is used for 2. Before you are given Cytarabine 3. How to use Cytarabine 4. Possible side effects 5. How to store Cytarabine 6. Further information 1. WHAT CYTARABINE IS AND WHAT IT IS USED FOR • Cytarabine is used in adults and children. The active ingredient is cytarabine. • Cytarabine is one of a group of medicines known as cytotoxics, these medicines are used in the treatment of acute leukaemias (cancer of blood where you have too many white blood cells).Cytarabine interferes with the growth of cancer cells, which are eventually destroyed. • Remission induction is an intensive treatment to force leukaemia into retreat. When it works, the balance of cells in your blood becomes more normal and your health improves. This relatively healthy period is called a remission. • Maintenance therapy is a milder treatment to make your remission last as long as possible. Quite low doses of cytarabine are used to keep the leukaemia under control and stop it flaring up again. 2. BEFORE YOU ARE GIVEN CYTARABINE DO NOT USE CYTARABINE IF YOU: • are allergic (hypersensitive) to cytarabine, or any of the other ingredients of cytarabine. • Läs hela dokumentet
Page 1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cytarabine 100 mg/ml solution for injection or infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 100 mg of cytarabine. Each 1 ml vial contains 100 mg of cytarabine. Each 5 ml vial contains 500 mg of cytarabine. Each 10 ml vial contains 1 g of cytarabine. Each 20 ml vial contains 2 g of cytarabine. Excipients: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free’. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for Injection or Infusion. clear, colourless solution. pH- 7.0 - 9.5 Osmolarity: 250 to 400 mOsm/L 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For induction of remission in acute myeloid leukaemia in adults and for other acute leukaemias of adults and children. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION By intravenous infusion or injection or subcutaneous injection. Subcutaneous injection is generally well tolerated, and may be recommended when used in maintenance therapy. CYTARABINE 100 MG/ML SHOULD NOT BE ADMINISTERED BY THE INTRATHECAL ROUTE. Page 2 of 12 Treatment with cytarabine should be initiated by, or be in consultation with, a doctor with extensive experience in treatment with cytostatics. Only general recommendations can be given, as acute leukaemia is almost exclusively treated with combinations of cytostatics. Dosage recommendations, may be made according to body weight (mg/kg) or according to BSA(mg/m 2 ). Dose recommendation may be converted from those in terms of bodyweight to those related to surfac Läs hela dokumentet